SIGNIFICANCE OF AGE AND CONCOMITANT PATHOLOGY WITH METABOLIC DISORDERS IN THE CARCINOGENESIS OF PROSTATE CANCER

  2. 2024
  3. SIGNIFICANCE OF AGE AND CONCOMITANT PATHOLOGY WITH METABOLIC DISORDERS IN THE CARCINOGENESIS OF PROSTATE CANCER

Nalbandian T. A., Antonyan I. M.

SIGNIFICANCE OF AGE AND CONCOMITANT PATHOLOGY WITH METABOLIC DISORDERS IN THE CARCINOGENESIS OF PROSTATE CANCER

Show/Download

About the author:

Nalbandian T. A., Antonyan I. M.

Heading:

LITERATURE REVIEWS

Type of article:

Scientific article

Annotation:

In Ukraine, as in the rest of the world, prostate cancer ranks first in the structure of cancer and is a leading cause of death among older men, with the highest incidence rates in the age group of 75-79 years and mortality rates in the age group of 80-84 years. The results of studies, systematic reviews and meta-analyses indicate that many factors of prostate cancer carcinogenesis cannot be modified (age and genetic predisposition associated with race or ethnicity or family history, etc.) and factors that can be corrected (diet, comorbidities, medications and other disorders that have a systemic effect on the body). The patient's age is associated with ageing, which is related to various metabolic disorders and leads to the development of comorbidities, among which the most notable are cardiovascular disease, obesity, diabetes mellitus, and metabolic syndrome. The metabolic dyslipidemia inherent in these diseases may contribute to carcinogenesis and is a potential target for therapeutic intervention in patients with prostate cancer. Preventing the development of lethal PCa is more important than reducing the overall incidence. However, modern methods of PCa treatment are aimed mainly at the proliferative activity of cells, which is absent in the cells of dormant metastases, making them resistant to standard methods of anticancer therapy, which gives grounds for justifying additional methods of treatment or correction of treatment tactics in patients with this pathology. A promising area is the active detection and timely correction of metabolic disorders in patients with PCa.

Tags:

age, diabetes mellitus, metabolic dyslipidemia, metabolic syndrome, obesity, prostate cancer

Bibliography:

  1. Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. 2022 Update on prostate cancer epidemiology and risk factors - a systematic review. Eur Urol. 2023;84(2):191-206. DOI: 10.1016/j.eururo. 2023.04.021.
  2. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. DOI: 10.3322/caac.21763.
  3. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. DOI: 10.3322/caac.21834.
  4. Taitt HE. Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location. Am. J. Men’s Health. 2018;12:1807-1823. DOI: 10.1177/15579 88318798279.
  5. Fedorenko ZP, Zuba VO, Horokh YeL, Hulak LO, Ryzhov AIu. Rak v Ukraini, 2021-2022. Zakhvoriuvanist’, smertnist’, pokaznyky diial’nosti onkolohichnoi sluzhby. Biuleten’ Natsional’noho kantser-reiestru Ukrainy № 24. Kyiv: Natsionalnyi kantserreiestr Ukrainy; 2023. 145 s. Dostupno: http://www.ncru.inf.ua/publications/BULL_24. [in Ukrainian].
  6. Saidakova NO, Shulyak ОV, Startseva LM, Коnonova GЕ. Analysis of the state of urological care in Ukraine (2019-2020). Urologia. 2021;25(4):295-299. DOI: 10.26641/2307-5279.25.4.2021.253391.
  7. Kukuruza H, Kukhar M, Lesyk M, Liubchenko O. Analiz vplyvu na VVP ta derzhavni finansy zakhvoriuvanosti na rak peredmikhurovoi zalozy ta yakosti yoho likuvannia v Ukraini. Ukr. med. chasopys. 2023;5(157):1-7 DOI: 10.32471/umj.1680-3051.157.248119. [in Ukrainian].
  8. Ziuzin VO, Savel’iev AO, Tuzova OV, Frolov YuA, Muntian LIa. Analiz zakhvoriuvanosti na rak peredmikhurovoi zalozy ta stan orhanizatsii onkolohichnoi dopomohy khvorym v Ukraini. Ukrains’kyi zhurnal medytsyny, biolohii ta sportu. 2022;7(4(38)):83-88. [in Ukrainian].
  9. Fedorenko ZP, Horokh YeL, Hulak LO, Kutsenko LB, Sumkina OV, Ryzhov AIu. Rak v Ukraini, 2020-2021. Zakhvoriuvanist’, smertnist’, pokaznyky diial’nosti onkolohichnoi sluzhby. Biuleten’ Natsional’noho kantser-reiestru Ukrainy № 23. Kyiv: Natsionalnyi kantserreiestr Ukrainy; 2022. 129 s. Dostupno: http://www.ncru.inf.ua/publications/BULL_23. [in Ukrainian].
  10. Tymoshenko AV. Osoblyvosti vplyvu metabolichnoho syndromu na ahresyvnist’ perebihu raku peredmikhurovoi zalozy. Klinichna onkolohiia. 2023;13(2):123-126. [in Ukrainian].
  11. Barsouk A, Padala SA, Vakiti A, Mohammed A, Saginala K, Thandra KC, et al. Epidemiology, staging and management of prostate cancer. Med Sci (Basel). 2020;8(3):28. DOI: 10.3390/medsci8030028.
  12. Berglund A, Garmo H, Tishelman C, Holmberg L, Stattin P, Lambe M. Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden. J Urol. 2011;185(3):833-9. DOI: 10.1016/j.juro.2010.10.061.
  13. Campi R, Brookman-May SD, Subiela Henríquez JD, Akdoğan B, Brausi M, Klatte T, et al. Impact of metabolic diseases, drugs, and dietary factors on prostate cancer risk, recurrence, and survival: a systematic review by the European association of urology section of oncological urology. Eur Urol Focus. 2019; 5(6):1029-1057. DOI: 10.1016/j.euf.2018.04.001.
  14. Rajan P, Sooriakumaran P, Nyberg T, Akre O, Carlsson S, Egevad L, et al. Effect of Comorbidity on Prostate Cancer-Specific Mortality: A Prospective Observational Study. J Clin Oncol. 2017;35(31):3566-3574. DOI: 10.1200/JCO.2016.70.7794.
  15. Varaprasad GL, Gupta VK, Prasad K, Kim E, Tej MB, Mohanty P, et al. Recent advances and future perspectives in the therapeutics of prostate cancer. Exp Hematol Oncol. 2023;12(1):80. DOI: 10.1186/s40164-023-00444-9.
  16. WHO. Ageing and health. Geneva: WHO; 2024. Available from: https://www.who.int/news-room/fact-sheets/detail/ageing-and-health.
  17. Derzhavna sluzhba statystyky Ukrainy. Statystychnyi zbirnyk Rozpodil postiinoho naselennia Ukrainy za stattiu ta vikom na 1 sichnia 2022 roku. Kyyiv: Derzhavna sluzhba statystyky Ukrainy; 2022. 20 s. [in Ukrainian].
  18. Frol’kis V. Mekhanizmy starinnia y prodovzhennia zhyttia. Praktykuiuchyi likar. 2017;6(2):57-66. [in Ukrainian].
  19. Clement J, Wong M, Poljak A, Sachdev P, Braidy N. The plasma NAD+ metabolome is dysregulated in “normal” aging. Rejuvenation Res. 2019;22:121-130. DOI: 10.1089/rej.2018.2077.
  20. Xiao W, Wang RS, Handy DE, Loscalzo J. NAD(H) and NADP(H) Redox couples and cellular energy metabolism. Antioxidants Redox Signal. 2018;28:251-272. DOI: 10.1089/ars.2017.7216.
  21. Adav SS, Wang Y. Metabolomics Signatures of Aging: Recent Advances. Aging Dis. 2021;12(2):646-661. DOI: 10.14336/AD.2020.0909.
  22. Jasbi P, Nikolich-Žugich J, Patterson J, Knox KS, Jin Y, Weinstock GM, et al. Targeted metabolomics reveals plasma biomarkers and metabolic alterations of the aging process in healthy young and older adults. Geroscience. 2023;45(6):3131-3146. DOI: 10.1007/s11357- 023-00823-4.
  23. Chak CM, Lacruz ME, Adam J, Brandmaier S, Covic M, Huang J, et al. Ageing Investigation Using Two-Time-Point Metabolomics Data from KORA and CARLA Studies. Metabolites. 2019;9(3):44. DOI: 10.3390/metabo9030044.
  24. Clark R, Vesprini D, Narod SA. The effect of age on prostate cancer survival. Cancers (Basel). 2022;14(17):4149. DOI: 10.3390/cancers1417 4149.
  25. Abudoubari S, Bu K, Mei Y, Maimaitiyiming A, An H, Tao N. Prostate cancer epidemiology and prognostic factors in the United States. Front Oncol. 2023;13:1142976. DOI: 10.3389/fonc.2023.1142976.
  26. Kerr J, Anderson C, Lippman SM. Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence. Lancet Oncol. 2017;18(8):e457-e471. DOI: https://doi.org/10.1016/S1470-2045(17)30411.
  27. Riscuta G. Nutrigenomics at the Interface of Aging, Lifespan, and Cancer Prevention. J Nutr. 2016;146(10):1931-1939.
  28. Zitvogel L, Pietrocola F, Kroemer G. Nutrition, inflammation and cancer. Nat Immunol. 2017;18(8):843-850. DOI: https://doi.org/10.1038/ ni.3754.
  29. Cui H, Zhang W, Zhang L, Qu Y, Xu Z, Tan Z, et al. Risk factors for prostate cancer: An umbrella review of prospective observational studies and mendelian randomization analyses. PLoS Med. 2024;21(3):e1004362. DOI: 10.1371/journal.pmed.1004362.
  30. Sawada N. Risk and preventive factors for prostate cancer in Japan: The Japan Public Health Center-based prospective (JPHC) study. J Epidemiol. 2017;27(1):2-7. DOI: 10.1016/j.je.2016.09.001.
  31. Alemany M. The Metabolic Syndrome, a Human Disease. Int J Mol Sci. 2024;25(4):2251. DOI: 10.3390/ijms25042251.
  32. Harborg S, Kjærgaard KA, Thomsen RW, Borgquist S, Cronin-Fenton D, Hjorth CF. New horizons: epidemiology of obesity, diabetes mellitus, and cancer prognosis. J Clin Endocrinol Metab. 2024;109(4):924-935. DOI: 10.1210/clinem/dgad450.
  33. WHO. Obesity and Overweight. Geneva: World Health Organization; 2024. Available from: https://www.who.int/news-room/fact-sheets/ detail/obesity-and-overweight.
  34. International Diabetes Federation (IDF). IDF Diabetes Atlas. 10th ed. Brussels: International Diabetes Federation; 2022. 141 p. Available from: https://diabetesatlas.org/atlas/tenth-edition/.
  35. Indeks zdorov’ya. Ukrayina. Dani doslidzhennya “Indeks zdorov’ya. Ukrayina” - 2020. Indeks zdorov’ya. Ukrayina; 2020. 52 s. Dostupno: https://health-index.com.ua/upload/ckeditor/4118d8ca989e4e55618fa58d22 34fbf9.pdf. [in Ukrainian].
  36. Pati S, Irfan W, Jameel A, Ahmed S, Shahid RK. Obesity and cancer: a current overview of epidemiology, pathogenesis, outcomes, and management. Cancers (Basel). 2023;15(2):485. DOI: 10.3390/cancers 15020485.
  37. Mauvais-Jarvis F. Sex differences in metabolic homeostasis, diabetes, and obesity. Biol Sex Differ. 2015;6:14. DOI: 10.1186/s13293-015- 0033-y.
  38. Häggström C, Van Hemelrijck M, Zethelius B, Robinson D, Grundmark B, Holmberg L, et al. Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer. Int J Cancer. 2017;140(3):611-617. DOI: 10.1002/ijc.30480.
  39. Goncalves SC, de Moraes Siqueira R, Nogueira MVF, Pereira-Correia JA, Vaz FP, Peres WAF. The Relationship Between Prostate Cancer Aggressiveness and Glycemic Levels in Patients Submitted to Radical Prostatectomy. World J Oncol. 2013;4(2):87-94. DOI: 10.4021/ wjon664e.
  40. Crawley D, Chamberlain F, Garmo H, Rudman S, Zethelius B, Holmberg L, et al. A systematic review of the literature exploring the interplay between prostate cancer and type two diabetes mellitus. Ecancermedicalscience. 2018;12:802. DOI: 10.3332/ecancer.2018.802.
  41. Lee J, Giovannucci E, Jeon JY. Diabetes and mortality in patients with prostate cancer: a meta-analysis. Springerplus. 2016;5(1):1548. DOI: 10.1186/s40064-016-3233-y.
  42. Nik-Ahd F, Howard LE, Eisenberg AT, Aronson WJ, Terris MK, Cooperberg MR, et al. Poorly controlled diabetes increases the risk of metastases and castration-resistant prostate cancer in men undergoing radical prostatectomy: Results from the SEARCH database. Cancer. 2019;125(16):2861-2867. DOI: 10.1002/cncr.32141.
  43. Kelkar S, Oyekunle T, Eisenberg A, Howard L, Aronson WJ, Kane CJ, et al. Diabetes and prostate cancer outcomes in obese and nonobese men after radical prostatectomy. JNCI Cancer Spectr. 2021;5(3):pkab023. DOI: 10.1093/jncics/pkab023.
  44. Su X, Cheng Y, Zhang G, Wang B. Novel insights into the pathological mechanisms of metabolic related dyslipidemia. Mol Biol Rep. 2021;48(7):5675-5687. DOI: 10.1007/s11033-021-06529-0.
  45. Feunteun J, Ostyn P, Delaloge S. Tumor cell malignancy: A complex trait built through reciprocal interactions between tumors and tissue-body system. iScience. 2022;25(5):104217. DOI: 10.1016/j.isci.2022.104217.
  46. Neshat S, Rezaei A, Farid A, Sarallah R, Javanshir S, Ahmadian S. The tangled web of dyslipidemia and cancer: Is there any association? J Res Med Sci. 2022;27:93. DOI: 10.4103/jrms.jrms_267_22.
  47. Zhong GC, Huang SQ, Peng Y, Wan L, Wu YQ, Hu TY, et al. HDL-C is associated with mortality from all causes, cardiovascular disease and cancer in a J-shaped dose-response fashion: a pooled analysis of 37 prospective cohort studies. Eur J Prev Cardiol. 2020;27(11):1187- 1203. DOI: 10.1177/2047487320914756.
  48. Barbalata CI, Tefas LR, Achim M, Tomuta I, Porfire AS. Statins in risk-reduction and treatment of cancer. World J Clin Oncol. 2020;11(8):573- 588. DOI: 10.5306/wjco.v11.i8.573.
  49. Siltari A, Syvälä H, Lou YR, Gao Y, Murtola TJ. Role of Lipids and Lipid Metabolism in Prostate Cancer Progression and the Tumor’s Immune Environment. Cancers (Basel). 2022;14(17):4293. DOI: 10.3390/cancers 14174293.
  50. Singh G, Sankanagoudar S, Dogra P, Chandra NC. Interlink between cholesterol & cell cycle in prostate carcinoma. Indian J Med Res. 2017;146:S38-S44. DOI: 10.4103/ijmr.IJMR_1639_15.
  51. Rosha LH, Lysenko VV. Morfolohichni osoblyvosti kastratsiino-rezystentnoho raku peredmikhurovoi zalozy. Dosiahnennia biolohii ta medytsyny. 2018;2(32):34-36. [in Ukrainian].
  52. Jung YY, Ko JH, Um JY, Chinnathambi A, Alharbi SA, Sethi G, et al. LDL cholesterol promotes the proliferation of prostate and pancreatic cancer cells by activating the STAT3 pathway. J Cell Physiol. 2021;236(7):5253-5264. DOI: 10.1002/jcp.30229.
  53. Kim J, Di Vizio D, Kim TK, Kim J, Kim M, Pelton K, et al. The response of the prostate to circulating cholesterol: activating transcription factor 3 (ATF3) as a prominent node in a cholesterol-sensing network. PLoS One. 2012;7(7):e39448. DOI: 10.1371/journal.pone.0039448.
  54. Ma HQ, Cui LH, Li CC, Yu Z, Piao JM. Effects of serum triglycerides on prostate cancer and breast cancer risk: a meta-analysis of prospective studies. Nutr Cancer. 2016;68(7):1073-82. DOI: 10.1080/01635581.2016. 1206582.
  55. Lebdai S, Mathieu R, Leger J, Haillot O, Vincendeau S, Rioux-Leclercq N et al. Metabolic syndrome and low high-density lipoprotein cholesterol are associated with adverse pathological features in patients with prostate cancer treated by radical prostatectomy. Urol Oncol. 2018;36(2):80.e17-80.e24. DOI: 10.1016/j.urolonc.2017.09.026.
  56. Zhou P, Li B, Liu B, Chen T, Xiao J. Prognostic role of serum total cholesterol and high-density lipoprotein cholesterol in cancer survivors: A systematic review and meta-analysis. Clin Chim Acta. 2018;477:94-104. DOI: 10.1016/j.cca.2017.11.039.
  57. Jamnagerwalla J, Howard LE, Allott EH, Vidal AC, Moreira DM, Castro-Santamaria R, et al. Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study. Prostate Cancer Prostatic Dis. 2018;21(2):252-259. DOI: 10.1038/s41391-017-0030-9.
  58. Bosco C, Wulaningsih W, Melvin J, Santaolalla A, De Piano M, Arthur R, et al. Metabolic serum biomarkers for the prediction of cancer: a follow-up of the studies conducted in the Swedish AMORIS study. Ecancermedicalscience. 2015;9:555. DOI: 10.3332/ecancer.2015.555.
  59. YuPeng L, YuXue Z, PengFei L, Cheng C, YaShuang Z, DaPeng L, et al. Cholesterol levels in blood and the risk of prostate cancer: a meta-analysis of 14 prospective studies. Cancer Epidemiol Biomarkers Prev. 2015;24(7):1086-93. DOI: 10.1158/1055-9965.EPI-14-1329.
  60. Cheng S, Zheng Q, Ding G, Li G. Influence of serum total cholesterol, LDL, HDL, and triglyceride on prostate cancer recurrence after radical prostatectomy. Cancer Manag Res. 2019;11:6651-6661. DOI: 10.2147/ CMAR.S204947.
  61. Arthur R, Møller H, Garmo H, Häggström C, Holmberg L, Stattin P, et al. Serum glucose, triglycerides, and cholesterol in relation to prostate cancer death in the Swedish AMORIS study. Cancer Causes Control. 2019;30(2):195-206. DOI: 10.1007/s10552-018-1093-1.
  62. Davies NM, Gaunt TR, Lewis SJ, Holly J, Donovan JL, Hamdy FC, et al. The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. Cancer Causes Control. 2015;26(11):1603-16. DOI: 10.1007/s10552-015-0654-9.
  63. Morote J, Ropero J, Planas J, Bastarós JM, Delgado G, Placer J et al. Metabolic syndrome increases the risk of aggressive prostate cancer detection. BJU Int. 2013;111(7):1031-6. DOI: 10.1111/j.1464-410X.2012. 11406.x.
  64. Colicchia M, Morlacco A, Rangel LJ, Carlson RE, Dal Moro F, Karnes RJ. Role of metabolic syndrome on perioperative and oncological outcomes at radical prostatectomy in a low-risk prostate cancer cohort potentially eligible for active surveillance. Eur Urol Focus. 2019;5(3):425-432. DOI: 10.1016/j.euf.2017.12.005.
  65. Xiang YZ, Xiong H, Cui ZL, Jiang SB, Xia QH, Zhao Y, et al. The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence. J Exp Clin Cancer Res. 2013;32(1):9. DOI: 10.1186/1756-9966-32-9.
  66. An H, Ma D, Mei Y, Wang L, Maimaitiyiming A, Zhuo T, et al. Metabolic syndrome and metastatic prostate cancer correlation study, a real-world study in a prostate cancer clinical research center, Xinjiang, China. Front Endocrinol (Lausanne). 2022;13:1090763. DOI: 10.3389/ fendo.2022. 1090763.
  67. Jeon KP, Jeong TY, Lee SY, Hwang SW, Shin JH, Kim DS. Prostate cancer in patients with metabolic syndrome is associated with low grade Gleason score when diagnosed on biopsy. Korean J Urol. 2012;53(9):593-7. DOI: 10.4111/kju.2012.53.9.593.
  68. Guerrios-Rivera L, Howard LE, Wiggins EK, Hoyo C, Grant DJ, Erickson TR, et al. Metabolic syndrome is associated with aggressive prostate cancer regardless of race. Cancer Causes Control. 2023;34(3):213-221. DOI: 10.1007/s10552-022-01649-9.
  69. Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Parretta E, et al. Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis. J Endocrinol Invest. 2013;36(2):132-9. DOI: 10.1007/BF03346748.
  70. Blanc-Lapierre A, Spence A, Karakiewicz PI, Aprikian A, Saad F, Parent MÉ. Metabolic syndrome and prostate cancer risk in a population-based case-control study in Montreal, Canada. BMC Public Health. 2015;15:913. DOI: 10.1186/s12889-015-2260-x.
  71. Vidal AC, Howard LE, Moreira DM, Castro-Santamaria R, Andriole GL Jr, Freedland SJ. Obesity increases the risk for high-grade prostate cancer: results from the REDUCE study. Cancer Epidemiol Biomarkers Prev. 2014;23(12):2936-42. DOI: 10.1158/1055-9965.EPI-14-0795.
  72. Bhindi B, Locke J, Alibhai SMH, Kulkarni GS, Margel DS, Hamilton RJ, et al. Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort. Eur Urol. 2015;67(1):64-70. DOI: 10.1016/j.eururo.2014.01.040.
  73. Dickerman BA, Torfadottir JE, Valdimarsdottir UA, Wilson KM, Steingrimsdottir L, Aspelund T, et al. Midlife metabolic factors and prostate cancer risk in later life. Int J Cancer. 2018;142(6):1166-1173. DOI: 10.1002/ijc.31142.

Publication of the article:

«Bulletin of problems biology and medicine», 2024 Issue 4, 175, 63-74 pages, index UDC 616.65-006.6:[616-008.9+616-053]-092

DOI:

10.29254/2077-4214-2024-4-175-63-74

2024 Issue 4, 175
age diabetes mellitus metabolic dyslipidemia metabolic syndrome obesity prostate cancer
27.12.2024
Was this article helpful?
3
2

Leave a Reply

Your email address will not be published. Required fields are marked *


The reCAPTCHA verification period has expired. Please reload the page.